In 2024, the trade exchange (includes international purchases and sales) of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C was US$40M.
In 2024, the states with the most international sales in Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were Ciudad de México (US$1.39M), Estado de México (US$108k), Jalisco (US$69.6k), and Baja California (US$9.86k).
The states with the most international purchases in 2024 were Ciudad de México (US$10.6M), Jalisco (US$9.98M), Baja California (US$1.1M), Guanajuato (US$663k), and Estado de México (US$599k).
In 2024, the main commercial destinations of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were United States (US$622k), Colombia (US$321k), Spain (US$156k), Peru (US$153k), and Panama (US$73.6k).
The main commercial origins of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C in 2024 were United States (US$11.9M), China (US$7.77M), Brazil (US$2.25M), Costa Rica (US$418k), and Spain (US$279k).
In the global context, the main exporting countries of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C in 2022 were China (US$1.24B), United States (US$772M), and France (US$744M). In the same year, the main importing countries of Heparin and its Salts; other Human or Animal Substances Prepared for Therapeutic or Prophylactic Uses, N.E.C were France (US$1.14B), Singapore (US$657M), and United States (US$415M).